BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21859900)

  • 1. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
    Cognetti F; Ruggeri EM; Felici A; Gallucci M; Muto G; Pollera CF; Massidda B; Rubagotti A; Giannarelli D; Boccardo F;
    Ann Oncol; 2012 Mar; 23(3):695-700. PubMed ID: 21859900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
    Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
    Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
    Zaghloul MS; Christodouleas JP; Smith A; Abdallah A; William H; Khaled HM; Hwang WT; Baumann BC
    JAMA Surg; 2018 Jan; 153(1):e174591. PubMed ID: 29188298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
    Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM
    Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
    Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
    Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
    Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
    J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
    Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
    Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
    Sternberg CN; Skoneczna IA; Castellano D; Theodore C; Blais N; Voog E; Bellmunt J; Peters F; Le-Guennec S; Cerbone L; Risse ML; Machiels JP
    Oncology; 2013; 85(4):208-15. PubMed ID: 24080920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
    Song YS; Cho JS; Cho KS; Doo SH; Chung BH; Kim SJ; Yang WJ; Song KH; Kim CI; Hong SJ
    Urol Int; 2010; 85(1):47-51. PubMed ID: 20234122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
    Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
    BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
    Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
    Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
    Rose TL; Harrison MR; Deal AM; Ramalingam S; Whang YE; Brower B; Dunn M; Osterman CK; Heiling HM; Bjurlin MA; Smith AB; Nielsen ME; Tan HJ; Wallen E; Woods ME; George D; Zhang T; Drier A; Kim WY; Milowsky MI
    J Clin Oncol; 2021 Oct; 39(28):3140-3148. PubMed ID: 34428076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
    Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
    Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
    J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
    Pouessel D; Bastuji-Garin S; Houédé N; Vordos D; Loriot Y; Chevreau C; Sevin E; Beuzeboc P; Taille A; Le Thuaut A; Allory Y; Culine S
    Clin Genitourin Cancer; 2017 Feb; 15(1):e45-e52. PubMed ID: 27554584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
    Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.